Valuation: Sinotherapeutics Inc.

Market Cap 4.44B 661M 580M 548M 499M 934M 63.34B 941M 6.55B 2.54B 32.36B 2.48B 2.43B 104B P/E 2024
35.9x
P/E 2025 88.2x
Enterprise Value 3.69B 550M 482M 456M 415M 777M 52.68B 783M 5.45B 2.11B 26.91B 2.06B 2.02B 86.5B EV / Sales 2024
7.4x
EV / Sales 2025 8.08x
Free-Float
24.34%
Yield 2024
0.62%
Yield 2025 0.36%
1 day-3.61%
1 week+6.81%
Current month+7.74%
1 month-0.40%
3 months+31.03%
6 months+6.70%
Current year+1.86%
1 week 9.26
Extreme 9.26
10.49
1 month 8.43
Extreme 8.43
10.49
Current year 7.02
Extreme 7.02
11.33
1 year 7.02
Extreme 7.02
11.46
3 years 6.3
Extreme 6.3
14
5 years 6.3
Extreme 6.3
28
10 years 6.3
Extreme 6.3
28
Manager TitleAgeSince
Chief Executive Officer 53 06/04/2023
Director of Finance/CFO 57 30/04/2025
Investor Relations Contact 44 31/05/2023
Director TitleAgeSince
Chairman 53 18/08/2020
Director/Board Member 58 01/08/2012
Director/Board Member 44 01/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.61%+6.81%-8.09%-13.10% 661M
+0.12%+0.81%+13.81%+64.78% 46.37B
+1.09%+0.36%+39.50%+107.67% 37.26B
+2.00%+3.78%+18.12%+99.54% 12.53B
+0.05%+0.37%-7.29%+18.68% 11.8B
0.00%0.00%+18.72%+139.63% 8.97B
-1.34%-2.73%+27.67%+37.52% 7.09B
-2.07%-2.75%+17.20%+202.97% 7.01B
+1.43%+2.22%+43.10%-14.21% 7.29B
-2.45%-0.59%-51.49%+4.53% 4.99B
Average -0.48%+0.83%+11.13%+64.80% 14.4B
Weighted average by Cap. +0.30%+0.57%+19.38%+78.73%

Financials

2024 2025
Net sales 512M 76.22M 66.88M 63.16M 57.56M 108M 7.3B 109M 756M 293M 3.73B 286M 280M 11.99B 447M 66.52M 58.38M 55.13M 50.24M 94.05M 6.38B 94.72M 660M 256M 3.26B 250M 244M 10.47B
Net income 128M 19.02M 16.69M 15.77M 14.37M 26.9M 1.82B 27.09M 189M 73.07M 931M 71.43M 69.88M 2.99B 47.48M 7.07M 6.21M 5.86M 5.34M 10M 678M 10.07M 70.15M 27.17M 346M 26.56M 25.98M 1.11B
Net Debt -734M -109M -95.89M -90.56M -82.53M -154M -10.47B -156M -1.08B -420M -5.35B -410M -401M -17.2B -746M -111M -97.57M -92.15M -83.98M -157M -10.66B -158M -1.1B -427M -5.44B -417M -408M -17.5B
Logo Sinotherapeutics Inc.
Sinotherapeutics Inc is a China-based company mainly engaged in the research and development, product registration, production and sales of generic drugs, as well as contract research organization/contract manufacture organization (CRO/CMO) services. The Company's main products include posaconazole enteric-coated tablets, mesalazine enteric-coated tablets, ursodeoxycholic acid capsules and others. The Company's products cover multiple fields including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, nephrology, and analgesia. The Company's CRO/CMO services are primarily formulation CRO/CMO services, providing pharmaceutical companies and research institutions with specialized formulation development services during drug development and commercial manufacturing services after drug approval through contracts. The Company mainly conducts its business in the domestic and overseas markets.
Employees
319
Date Price Change Volume
24/09/26 CNY 9.880 -3.61% 9,297,134
23/09/26 CNY 10.25 +2.40% 8,915,571
22/09/26 CNY 10.01 +0.50% 8,870,059
21/09/26 CNY 9.960 +7.68% 10,369,551
18/09/26 CNY 9.250 +0.76% 7,037,465
  1. Stock Market
  2. Stocks
  3. 688247 Stock